Search Results

BioMidwest

European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations

New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott’s CardioMEMS™ HF System resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor.

May 24, 2023

·

5 min read

FDA

Abbott’s CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company’s CardioMEMS™ HF System to support the care of more people living with heart failure.

February 21, 2022

·

5 min read

BioMidwest

GUIDE-HF Study Data Show Abbott’s CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure

Abbott (NYSE: ABT) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living with NYHA Class II, III and IV heart failure.

August 27, 2021

·

6 min read

BioMidwest

JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients

Daxor Corporation announces a new research letter in the Journal of the American College of Cardiology – Heart Failure validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

July 12, 2023

·

3 min read

New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

March 23, 2023

·

3 min read

Drug Development

Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor

Abbott announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System.

March 29, 2018

·

3 min read

Press Releases

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

October 25, 2024